Initial absolute lymphocyte count as a prognostic factor for outcome in acute myeloid leukemia

References

• Döhner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults:recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010;115:453–474.
   PubMed Web of Science ®Google Scholar
• Estey E, Döhner H. Acute myeloid leukaemia. Lancet 2006;368: 1894–1907.
   PubMed Web of Science ®Google Scholar
• Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998;92:2322–2333.
   PubMed Web of Science ®Google Scholar
• Blake-Mortimer JS, Sephton SE, Carlson RW, et al. Cytotoxic T lymphocyte count and survival time in women with metastatic breast cancer. Breast J 2004;10:195–199.
   PubMedGoogle Scholar
• Fumagalli LA, Vinke J, Hoff W, et al. Lymphocyte counts independently predict overall survival in advanced cancer patients: a biomarker for IL-2 immunotherapy. J Immunother 2003;26:394–402.
   PubMed Web of Science ®Google Scholar
• Fogar P, Sperti C, Basso D, et al. Decreased total lymphocyte counts in pancreatic cancer: an index of adverse outcome. Pancreas 2006;32:22–28.
   PubMed Web of Science ®Google Scholar
• Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003;348:203–213.
   PubMed Web of Science ®Google Scholar
• Cézé N, Thibault G, Goujon G, et al. Pre-treatment lymphopenia as a prognostic biomarker in colorectal cancer patients receiving chemotherapy. Cancer Chemother Pharmacol 2011;68:1305–1313.
   PubMed Web of Science ®Google Scholar
• Van Glabbeke M, Van Oosterom AT, Oosterhuis JW, et al. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens -- a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol 1999;17:150–157.
   PubMed Web of Science ®Google Scholar
• Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International prognostic factors project on advanced Hodgkin's disease. N Engl J Med 1998;339:1506–1514.
   PubMed Web of Science ®Google Scholar
• Oki Y, Yamamoto K, Kato H, et al. Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients’ survival benefit from rituximab. Eur J Haematol 2008;81:448–453.
   PubMed Web of Science ®Google Scholar
• Siddiqui M, Ristow K, Markovic SN, et al. Absolute lymphocyte count predicts overall survival in follicular lymphomas. Br J Haematol 2006;134:596–601.
   PubMed Web of Science ®Google Scholar
• Ege H, Gertz MA, Markovic SN, et al. Prediction of survival using absolute lymphocyte count for newly diagnosed patients with multiple myeloma: a retrospective study. Br J Haematol 2008;141:792–798.
   PubMed Web of Science ®Google Scholar
• Jacobs NL, Holtan SG, Porrata LF, et al. Host immunity affects survival in myelodysplastic syndromes:Independent prognostic value of the absolute lymphocyte count. Am J Hematol 2010;85:160–163.
   PubMed Web of Science ®Google Scholar
• Porrata LF, Rsitow K, Inwards DJ, et al. Lymphopenia assessed during routine follow-up after immunochemotherapy (R-CHOP) is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma. Leukemia 2010;24:1343–1349.
   PubMed Web of Science ®Google Scholar
• Behl D, Porrata LF, Markovic SN, et al. Absolute lymphocyte count recovery after induction chemotherapy predicts superior survival in acute myelogenous leukemia. Leukemia 2006;20:29–34.
   PubMed Web of Science ®Google Scholar
• Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 1976;33:451–458.
   PubMed Web of Science ®Google Scholar
• Chevallier P, Fornecker L, Lioure B, et al. Tandem versus single autologous peripheral blood stem cell transplantation as post-remission therapy in adult acute myeloid leukemia patients under 60 in first complete remission: results of the multicenter prospective phase III GOELAMS LAM-2001 trial. Leukemia 2010;24:1380–1385.
   PubMed Web of Science ®Google Scholar
• Lioure B, Bene MC, Pigneux A, et al. Early matched sibling hematopoietic cell transplantation for adult AML in first remission using an age-adapted strategy: long-term results of a prospective GOELAMS study. Blood 2012;119:2943–2948.
   PubMed Web of Science ®Google Scholar
• Pigneux A, Harousseau JL, Witz F, et al. Addition of lomustine to idarubicin and cytarabine improves the outcome of elderly patients with de novo acute myeloid leukemia: a report from the GOELAMS. J Clin Oncol 2010;28:3028–3034.
   PubMed Web of Science ®Google Scholar
• Archimbaud E, Thomas X, Michallet M, et al. Prospective genetically randomized comparison between intensive postinduction chemotherapy and bone marrow transplantation in adults with newly diagnosed acute myeloid leukemia. J Clin Oncol 1994;12:262–267.
   PubMed Web of Science ®Google Scholar
• Pautas C, Merabet F, Thomas X, et al. Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study. J Clin Oncol 2010;28:808–814.
   PubMed Web of Science ®Google Scholar
• Thomas X, Chelghoum Y, Cannas G, et al. Leukocytosis and circulating blasts in older adults with newly diagnosed acute myeloid leukemia: are they valuable factors for therapeutic decision-making?Clin Lymphoma Myeloma Leuk 2011;11:342–349.
   PubMed Web of Science ®Google Scholar
• Thomas X, Elhamri M, Raffoux E, et al. Comparison of high-dose cytarabine and timed-sequential chemotherapy as consolidation for younger adults with AML in first remission: the ALFA-9802 study. Blood 2011;118:1754–1762.
   PubMed Web of Science ®Google Scholar
• An International System for Human Cytogenetic Nomenclature (1985) ISCN 1985. Report of the Standing Committee on Human Cytogenetic Nomenclature. Birth Defects Orig Artic Ser 1985;21:1–117.
   Google Scholar
• Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 2003;21:4642–4649.
   PubMed Web of Science ®Google Scholar
• Rogers SY, Bradbury D, Kozlowski R, et al. Evidence for internal autocrine regulation of growth in acute myeloblastic leukemia cells. Exp Hematol 1994;22:593–598.
   PubMed Web of Science ®Google Scholar
• Oster W, Cicco NA, Klein H, et al. Participation of the cytokines interleukin 6, tumor necrosis factor-alpha, and interleukin 1-beta secreted by acute myelogenous leukemia blasts in autocrine and paracrine leukemia growth control. J Clin Invest 1989;84:451–457.
   PubMed Web of Science ®Google Scholar
• Thomas X, Hirschauer C, Troncy J, et al. Serum interleukin-6 levels in adult acute myelogenous leukemia:relationship with disease characteristics and outcome. Leuk Lymphoma 1997;24:291–300.
   PubMed Web of Science ®Google Scholar
• Blay JY, Farcet JP, Lavaud A, et al. Serum concentrations of cytokines in patients with Hodgkin's disease. Eur J Cancer 1994;30A:321–324.
   PubMed Web of Science ®Google Scholar
• Casasnovas RO, Mounier N, Brice P, et al. Plasma cytokine and soluble receptor signature predicts outcome of patients with classical Hodgkin's lymphoma: a study from the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 2007;25:1732–1740.
   PubMed Web of Science ®Google Scholar
• Ray-Coquard I, Borg C, Bachelot T, et al. Baseline and early lymphopenia predict for the risk of febrile neutropenia after chemotherapy. Br J Cancer 2003;88:181–186.
   PubMed Web of Science ®Google Scholar
• Ray-Coquard I, Cesne AL, Rubio MT, et al. Risk model for severe anemia requiring red blood cell transfusion after cytotoxic conventional chemotherapy regimens. J Clin Oncol 1999;17:2840–2840.
   PubMed Web of Science ®Google Scholar
• Blay JY, Cesne AL, Mermet C, et al. A risk model for thrombocytopenia requiring platelet transfusion after cytotoxic chemotherapy. Blood 1998;92:405–410.
   Google Scholar
• Ray-Coquard I, Ghesquière H, Bachelot T, et al. Identification of patients at risk for early death after conventional chemotherapy in solid tumours and lymphomas. Br J Cancer 2001;85:816–822.
   PubMedGoogle Scholar
• Borg C, Ray-Coquard I, Philip I, et al. CD4 lymphopenia as a risk factor for febrile neutropenia and early death after cytotoxic chemotherapy in adult patients with cancer. Cancer 2004;101:2675–2680.
   Google Scholar
• Lissoni P, Brivio F, Fumagalli L, et al. Efficacy of cancer chemotherapy in relation to the pretreatment number of lymphocytes in patients with metastatic solid tumors. Int J Biol Markers 2004;19:135–140.
   PubMed Web of Science ®Google Scholar
• Nelson DS. Immunity to infection, allograft immunity and tumour immunity: parallels and contrasts. Transplant Rev 1974;19:226–254.
   PubMedGoogle Scholar
• Hoffmann TK, Dworacki G, Tsukihiro T, et al. Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance. Clin Cancer Res 2002;8:2553–2562.
   PubMed Web of Science ®Google Scholar
• Dworacki G, Meidenbauer N, Kuss I, et al. Decreased zeta chain expression and apoptosis in CD3 + peripheral blood T lymphocytes of patients with melanoma. Clin Cancer Res 2001;7(Suppl. 3):947s–957s.
   PubMed Web of Science ®Google Scholar
• Lowdell MW, Craston R, Samuel D, et al. Evidence that continued remission in patients treated for acute leukaemia is dependent upon autologous natural killer cells. Br J Haematol 2002;117:821–827.
   PubMed Web of Science ®Google Scholar
• Fauriat C, Just-Landi S, Mallet F, et al. Deficient expression of NCR in NK cells from acute myeloid leukemia: evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction. Blood 2007;109:323–330.
   PubMed Web of Science ®Google Scholar
• Dauguet N, Recher C, Demur C, et al. Pre-eminence and persistence of immature natural killer cells in acute myeloid leukemia patients in first complete remission. Am J Hematol 2011;86:209–213.
   PubMed Web of Science ®Google Scholar
• Mackall CL, Fleisher TA, Brown MR, et al. Lymphocyte depletion during treatment with intensive chemotherapy for cancer. Blood 1994;84:2221–2228.
   PubMed Web of Science ®Google Scholar
• Rey J, Veuillen C, Vey N, et al. Natural killer and gammadelta T cells in haematological malignancies:enhancing the immune effectors. Trends Mol Med 2009;15:275–284.
   PubMed Web of Science ®Google Scholar
• Ray-Coquard I, Cropet C, Van Glabbeke M, et al. Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res 2009;69:5383–5391.
   PubMed Web of Science ®Google Scholar